Clinical Trial Update: A Study of LY2523355 in Participants With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study update for LY2523355 in metastatic breast cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• LY2523355

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-12-04